Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen, Inc. | 0.00% | 283.74 | 1.5% | $847.25m | |
| GILD | Gilead Sciences, Inc. | 0.00% | 86.26 | 1.0% | $795.01m | |
| MRNA | Moderna, Inc. | -0.52% | 175.49 | 0.0% | $765.23m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.11% | 312.63 | 1.9% | $481.47m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.50% | 732.55 | 2.6% | $470.92m | |
| BIIB | Biogen, Inc. | -3.37% | 294.88 | 1.8% | $343.12m | |
| ILMN | Illumina, Inc. | -0.70% | 217.46 | 3.2% | $268.84m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 0.00% | 2.78 | 0.7% | $194.33m | |
| BMRN | BioMarin Pharmaceutical, Inc. | 0.00% | 96.92 | 4.2% | $161.47m | |
| BNTX | BioNTech SE | -0.19% | 154.55 | 0.0% | $151.82m | |
| MRTX | Mirati Therapeutics, Inc. | 0.00% | 98.62 | 1.6% | $132.21m | |
| TECH | Bio-Techne Corp. | 0.00% | 338.97 | 4.5% | $123.89m | |
| AXSM | Axsome Therapeutics, Inc. | 0.00% | 56.82 | 1.6% | $80.71m | |
| NVAX | Novavax, Inc. | 0.00% | 16.54 | 75.3% | $70.44m | |
| HALO | Halozyme Therapeutics, Inc. | 0.00% | 54.67 | 18.4% | $64.50m |
Company Profile
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.